Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)

Stopped early · Phase 1/Phase 2

Conditions studied: Non-Small Cell Lung Cancer

In brief

The purpose of this study is to evaluate the safety and efficacy of avelumab when combined with either crizotinib or PF-06463922.

Key facts

Study ID
NCT02584634
Run by
Pfizer
People needed
43
Starts
2015-12-18
Expected to finish
2022-07-13
Last updated by the study team
2023-07-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.